Replies to post #131278 on Biotech Values

[kamehameha]

he NEUTRINO trial will enroll all genotypes who can not take interferon, including (and probably many) GT1 patients. The GT2/3 group is a sweet-spot for VRUS and based on data from ELECTRON trial, there's a very good chance that PSI-7977/RBV can cure these patients in 12 weeks.

so the label will be restricted to:
patients with GT2/3 and
patients with GT 1 who can not tolerate INF?

[oc631]

Not only in GT2/3: the NEUTRINO trial will enroll all genotypes who can not take interferon, including (and probably many) GT1 patients.

The majority of patients enrolled in NEUTRINO will be GT1. VRUS actually has two sweet spots to focus on


1- GT2/GT3 patients

2- Interferon-intolerant patients.


GT2/GT3 patients have the option of 24-weeks of Peg/Riba and a sub-par SVR rate. Interferon-intolerant patients have no option at all.